BRPI0719319A2 - Liberação colônica usando contas de zn/pectina com um revestimento de eudragit - Google Patents

Liberação colônica usando contas de zn/pectina com um revestimento de eudragit Download PDF

Info

Publication number
BRPI0719319A2
BRPI0719319A2 BRPI0719319-0A BRPI0719319A BRPI0719319A2 BR PI0719319 A2 BRPI0719319 A2 BR PI0719319A2 BR PI0719319 A BRPI0719319 A BR PI0719319A BR PI0719319 A2 BRPI0719319 A2 BR PI0719319A2
Authority
BR
Brazil
Prior art keywords
human
agent
drug delivery
beta
rat
Prior art date
Application number
BRPI0719319-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Antoine Andremont
Helene-Celine Huguet
Original Assignee
Da Volterra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Da Volterra filed Critical Da Volterra
Publication of BRPI0719319A2 publication Critical patent/BRPI0719319A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0719319-0A 2006-11-17 2007-11-16 Liberação colônica usando contas de zn/pectina com um revestimento de eudragit BRPI0719319A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85960006P 2006-11-17 2006-11-17
US85959906P 2006-11-17 2006-11-17
US60/859,599 2006-11-17
US60/859,600 2006-11-17
PCT/EP2007/062475 WO2008059062A1 (en) 2006-11-17 2007-11-16 Colonic delivery using zn/pectin beads with a eudragit coating.

Publications (1)

Publication Number Publication Date
BRPI0719319A2 true BRPI0719319A2 (pt) 2014-02-04

Family

ID=39181811

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0719319-0A BRPI0719319A2 (pt) 2006-11-17 2007-11-16 Liberação colônica usando contas de zn/pectina com um revestimento de eudragit

Country Status (7)

Country Link
EP (1) EP2081557A1 (zh)
JP (1) JP2010510196A (zh)
CN (1) CN101795675A (zh)
AU (1) AU2007321111A1 (zh)
BR (1) BRPI0719319A2 (zh)
CA (1) CA2678131A1 (zh)
WO (1) WO2008059062A1 (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2187953A2 (en) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of a peptide as a therapeutic agent
KR20100057641A (ko) * 2007-09-11 2010-05-31 몬도바이오테크 래보래토리즈 아게 인터메딘 ４７ 및 ５３ 펩티드의 치료적 용도
JP2010538994A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 例えば肺炎連鎖球菌感染症を治療するためのｂｆｇｆ１−２４および任意での（ａｒｇ８）バソプレシンの使用
CZ302789B6 (cs) 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
CA2790811C (en) * 2010-02-23 2017-12-05 Da Volterra Formulations for oral delivery of adsorbents in the gut
EP2555808A1 (en) * 2010-04-08 2013-02-13 Merz Pharma GmbH & Co. KGaA Fillers comprising gellan or pectin beads
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
BR112015023124A2 (pt) * 2013-03-14 2017-07-18 Therabiome Llc liberação de organismos probióticos e/ou agentes terapêuticos almejada para o trato gastrintestinal
EP3858437A1 (en) * 2013-04-26 2021-08-04 La Jolla Pharma, LLC Compositions and methods for treating renal failure
WO2015066212A2 (en) * 2013-10-31 2015-05-07 University Of Hawaii Calpain inhibitors for treatment of inflammatory bowel disease and colorectal cancer
CA2933601A1 (en) 2013-12-18 2015-06-25 The George Washington University, A Congressional Chartered Not-For-Prit Corporation Angiotensin ii alone or in combination for the treatment of hypotension
US10206884B2 (en) 2013-12-20 2019-02-19 Fresenius Kabi Deutschland Gmbh Microcapsules with polymeric coating comprising a lipid and an active agent
CN107072950B (zh) * 2014-09-11 2020-11-03 嘉利达股份有限公司 明胶/果胶粒子
US20160158174A1 (en) * 2014-12-09 2016-06-09 Intercontinental Great Brands Llc Enteric-Coated Functional Food Ingredients And Methods For Making The Enteric-Coated Functional Food Ingredients
JP2019501201A (ja) 2016-01-07 2019-01-17 ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ アンジオテンシンｉｉの投与方法
CA3029469A1 (en) * 2016-06-28 2018-01-04 Synthetic Biologics, Inc. Microbiome protection from oral antibiotics
US11771656B2 (en) * 2016-11-17 2023-10-03 Shanghai Jiaotong University School Of Medicine Oral colon-targeted delivery system and preparation method and application thereof
DE102017000896A1 (de) * 2017-02-01 2018-08-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Selektives Freisetzungssystem für Tumortherapeutika und Tumordiagnostika sowie Biosensor für Tumorgewebe
WO2018191678A1 (en) 2017-04-14 2018-10-18 La Jolla Pharmaceutical Company Methods for administering angiotensin ii

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
DE602005021475D1 (de) * 2004-03-26 2010-07-08 Lek Pharmaceuticals Magenresistente pharmazeutische dosierform mit n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutaminsäure (lk-423)
WO2006122835A1 (en) * 2005-05-18 2006-11-23 Da Volterra Colonic delivery of adsorbents

Also Published As

Publication number Publication date
AU2007321111A1 (en) 2008-05-22
CA2678131A1 (en) 2008-05-22
CN101795675A (zh) 2010-08-04
JP2010510196A (ja) 2010-04-02
WO2008059062A1 (en) 2008-05-22
EP2081557A1 (en) 2009-07-29

Similar Documents

Publication Publication Date Title
BRPI0719319A2 (pt) Liberação colônica usando contas de zn/pectina com um revestimento de eudragit
US20080124279A1 (en) Colonic delivery using Zn/pectin beads with a Eudragit coating
US20080317666A1 (en) Colonic Delivery of Active Agents
Huang et al. Development of novel nanoantibiotics using an outer membrane vesicle-based drug efflux mechanism
KR101080577B1 (ko) 활성성분의 결장 표적화 전달을 위한 제제
JP5829003B2 (ja) 単独でのまたは分解性分子と併用での吸着剤の部位特異的腸内送達
EP2642978B1 (en) Immunomodulatory compositions comprising hydralazine and cyclosporine a for the treatment of gastrointestinal disorders
JP4969013B2 (ja) 抗菌剤の経口吸収を改善するための組成物および方法
Mehta et al. Need of colon specific drug delivery system: review on primary and novel approaches
US20220062188A1 (en) All-in-one fixed-dose combination for treating helicobacter pylori infection
RU2282462C2 (ru) Композиции и способы улучшения перорального всасывания противомикробных средств
AU2014218599B2 (en) Guanylate cyclase receptor agonists for use in colonic cleansing
JP2002521346A (ja) 多糖類を利用した大腸選択性薬物伝達組成物および医薬製剤
KR20190127984A (ko) 지연 방출형 약물 제형
Kim et al. Fusogenic porous silicon nanoparticles as a broad-spectrum immunotherapy against bacterial infections
Gupta A review article on colonic targeted drug delivery system
US8273376B2 (en) Colonic delivery of metallo-dependent enzymes
JP2002504906A (ja) 下痢症状を治療し且つ腸管から特定細菌個体群を除去する方法
Ji et al. Guar gum as potential film coating material for colon-specific delivery of fluorouracil
JPWO2004028567A1 (ja) 薬物吸収性改善剤
Patel et al. Colon targeted drug delivery: Approaches and newer technology
Goracinova et al. Drug targeting in IBD treatment–Existing and new approaches

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired